Key result
Clopidogrel shows no difference versus prasugrel in stent thrombosis or bleeding after aneurysm stenting.
Why the study?
Clopidogrel is widely used for dual antiplatelet therapy during endovascular treatment of unruptured intracranial aneurysms, but its variable bioactivation and high on-treatment platelet reactivity have prompted interest in comparing it against alternatives like prasugrel.
Does clopidogrel compared with prasugrel (each combined with aspirin) affect thromboembolic and hemorrhagic outcomes in adults undergoing endovascular treatment of unruptured intracranial aneurysms?
Cohort (n=1,422)
Yes
Does clopidogrel compared with prasugrel (each combined with aspirin) affect thromboembolic and hemorrhagic outcomes in adults undergoing endovascular treatment of unruptured intracranial aneurysms?
Answers are grounded in this paper and cite their sources.
In a large propensity-matched real-world cohort undergoing endovascular treatment for unruptured intracranial aneurysms, prasugrel and clopidogrel showed no significant differences in 6-month or 1-year thromboembolic or hemorrhagic outcomes, supporting prasugrel as a reasonable alternative P2Y12 inhibitor.
Background Endovascular treatment of unruptured intracranial aneurysms (UIAs) often requires dual antiplatelet therapy with aspirin and a P2Y12 inhibitor. Clopidogrel remains widely used, but variable bioactivation and high on-treatment platelet reactivity have prompted interest in alternatives such as prasugrel. We compared thromboembolic and hemorrhagic outcomes after clopidogrel versus prasugrel use in endovascular UIA treatment. Methods We queried the TriNetX Global Collaborative Network for adults with UIA who underwent endovascular treatment between 2016 and 2025 and received aspirin plus clopidogrel or prasugrel. Cohorts were matched 1:1 using propensity score matching based on demographics and comorbidities. Outcomes were assessed at 6 months and 1 year and reported as odds ratios (ORs) with 95% confidence intervals (CIs). Results Among 15,496 adults, 711 matched pairs were included. At 6 months, no significant differences were observed for in-stent thrombosis (OR 0.77, 95% CI 0.38–1.57; p=0.47), cerebral infarction (OR 1.04, 95% CI 0.75–1.46; p=0.80), cerebral hemorrhage (OR 1.07, 95% CI 0.80–1.44; p=0.65), or gastrointestinal hemorrhage (OR 0.84, 95% CI 0.43–1.64; p=0.61). Findings remained nonsignificant at 1 year. Conclusions In this propensity-matched TriNetX analysis, clopidogrel and prasugrel were not associated with significant differences in thromboembolic or hemorrhagic outcomes after endovascular UIA treatment. Prasugrel may be a reasonable alternative P2Y12 inhibitor in selected patients, including those with suspected or documented clopidogrel non-response.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2026) conducted a cohort in Unruptured intracranial aneurysms undergoing endovascular treatment (n=1,422). Clopidogrel plus aspirin vs. Prasugrel plus aspirin was evaluated on In-stent thrombosis at 6 months (OR 0.77, 95% CI 0.38–1.57, p=0.47). Clopidogrel versus prasugrel showed no significant difference in 6-month in-stent thrombosis or hemorrhage after endovascular intracranial aneurysm treatment.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: